SMN1 and proximal spinal muscular atrophy: Based on these affirmative results, in May 2019 FDA approved onasemnogene abeparvovec for the treatment of SMA patients with less than two years of age with bi-allelic mutations in the SMN1 gene, including those who are pre-symptomatic at diagnosis [52].